Improved metabolism and redox state with a novel preservation solution: Implications for donor lungs after cardiac death (DCD) by Schipper, D.A. (David) et al.
Research Article
Improved metabolism and redox state with a novel
preservation solution: implications for donor lungs
after cardiac death (DCD)
David A. Schipper1,2, Anthony V. Louis1, Destiny S. Dicken1, Kitsie Johnson1,
Ryszard T. Smolenski3, Stephen M. Black4, Ray Runyan5, John Konhilas5, Joe G.N. Garcia4,5
and Zain Khalpey1,4
1University of Arizona College of Medicine, Department of Surgery, Division of Cardiothoracic Surgery, Tucson, AZ, USA; 2Division of Experimental Cardiology,
Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; 3Medical University of Gdan´sk, Department of
Biochemistry, Gdan´sk, Poland; 4University of Arizona College of Medicine, Department of Medicine, Division of Translational and Regenerative Medicine,
Tucson, AZ, USA; 5University of Arizona, Health Sciences Center, Tucson, AZ, USA
Abstract
Lungs donated after cardiac death (DCD) are an underutilized resource for a dwindling donor lung transplant pool. Our study
investigates the potential of a novel preservation solution, Somah, to better preserve statically stored DCD lungs, for an extended
time period, when compared to low-potassium dextran solution (LPD). We hypothesize that Somah is a metabolically superior
organ preservation solution for hypothermic statically stored porcine DCD lungs, possibly improving lung transplant outcomes.
Porcine DCD lungs (n¼ 3 per group) were flushed with and submerged in cold preservation solution. The lungs were stored up to
12 h, and samples were taken from lung tissue and the preservation medium throughout. Metabolomic and redox potential were
analyzed using high performance liquid chromatography, mass spectrometry, and RedoxSYS, comparing substrate and pathway
utilization in both preservation solutions. Glutathione reduction was seen in Somah but not in LPD during preservation. Carnitine,
carnosine, and n-acetylcarnosine levels were elevated in the Somah medium compared with LPD throughout. Biopsies of Somah
exposed lungs demonstrated similar trends after 2 h, up to 12 h. Adenosine gradually decreased in Somah medium over 12 h, but
not in LPD. An inversely proportional increase in inosine was found in Somah. Higher oxidative stress levels were measured in LPD.
Our study suggests suboptimal metabolic preservation in lungs stored in LPD. LPD had poor antioxidant potential, cytoprotection,
and an insufficient redox potential. These findings may have immediate clinical implications for human organs; however, further
investigation is needed to evaluate DCD lung preservation in Somah as a viable option for transplant.
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Lung transplantation is the only treatment for end-stage
lung failure. Despite various attempts to increase graft avail-
ability, lung transplant suﬀers from a critical lack of suitable
donor organs.1 Fewer than 20% of post-mortem donor
lungs are acceptable for transplantation and despite aggres-
sive care, ten-year survival is only 29–31%.2,3 While the
majority of donor organs are donated after brain death
(DBD), substantial evidence supports utilization of lungs
donated after cardiac death (DCD), which would consider-
ably increase the donor lung supply.1,4 Common barriers to
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both DBD and DCD availability are ischemia-induced lung
inﬂammation, vascular leakage, and ischemia reperfusion
(IR) injury occurring immediately after death and during
the delay between recovery and transplant into the
recipient.5,6
Over the past decades, promising prospectives have
emerged in DCD lung utilization for transplant. The critical
issue of warm ischemic times in a DCD setting has been
addressed by continuous ex vivo lung perfusion (EVLP).7
This approach has notable potential to expand the pool of
available organs, both by assessment of graft quality as well
as extending preservation time.8–10 Nonetheless, in the past
15 years EVLP has not been a solution capable of diminish-
ing the transplant gap. One important reason is that the lung
evaluated in these experiments fall under Maastricht criteria
III, with DCD occurring in a controlled hospital environ-
ment. Despite the impressive results demonstrated, the frac-
tion of lungs addressed is only marginal, as the majority of
possible DCD donations takes place after uncontrolled
death, following Maastricht criteria I and II (Table 1).
Expanding the DCD donor pool with lungs that fall under
category I and II would clearly have enormous impact on
the amount of available grafts. The use of Maastricht cri-
teria III DCD lungs for transplant is generally considered as
safe as DBD lung transplantation.11,12 In addition to the
relatively small number of DCD grafts that can be donated
when solely focusing on Maastricht criteria III lungs, the
limited number of medical institutions in possession of
EVLP infrastructure stands in the way of this new approach
from eliminating the donor lung scarcity. EVLP could be of
enormous contribution in transplant, yet its biggest addition
should be considered as a technique to improve and reju-
venate marginal lungs.13–15 The study here presented there-
fore proposes a novel cold static storage solution to enhance
current clinical procedures for DCD lungs donated for
transplant.
A critical factor in transplant success is preserving the
donor organ in optimal physiological condition between
the time of collection and transplant. Current practice uni-
versally involves an ex vivo lung preservation technique
based on cold static storage in a low-potassium dextran
solution (LPD, Perfadex) (Table 2). This solution provides
protection against tissue edema, while the low temperature
achieves a decrease in metabolic demand of the organ.
Although LPD provides protection for up to 6 h of storage16
minimizing energy needs by hypothermia alone has not
extended lung preservation time in clinical practice.
Furthermore, IR injury occurs when blood ﬂow is restored
and oxygen is delivered to the lungs following implantation
of a cold, statically stored organ. IR injury leads to apop-
tosis or necrosis of organ tissue triggered by mitochondrial
disrupture.17,18 In order to prevent irreversible damage to
the organ, it is critical to provide metabolic protection in
addition to the traditional methods currently used for donor
lung storage with LPD.
A novel solution, Somah (Table 2), aims to extend the ex
vivo longevity of organs by supplying metabolic needs
rather than minimizing energetic demand, while providing
reactive oxygen species (ROS) scavenging agents and tissue
protection. Studies using porcine hearts have demonstrated
the potential beneﬁt of Somah for cardiac transplantation in
hypothermic and subnormothermic settings.19,20 However,
in order to fully evaluate a novel solution’s mechanism and
clinical potential, assessment metabolic and redox pathways
are required. By investigating the metabolomics and redox
aspects of this novel solution and comparison with the
Table 2. Composition of organ preservation solutions investigated,
mmol/L.
Ingredient (mmol/L) Somah Perfadex
Naþ 125 138
Kþ 7 6
Mg2þ – 0.8
Cl – 142
KCl 7 0.4
MgCl2 0.5 –
NaCO3H 5 –
MgSO4 0.5 0.8
Glucose 11 5
Adenosine 2 –
Dextran 40 – 5%
Glutathione 1.5 –
CaCl2 1.3 –
Phosphate 0.44 0.8
Insulin 1 –
l-Arginine 5 –
l-Citrulline malate 1 –
Creatine orotate 0.5 –
Creatine monohydrate 2 –
l-Carnosine 10 –
l-Carnitine 10 –
Dichloroacetate 0.5 –
Ascorbic acid 1 –
Sodium phosphate 0.19 –
pH (at 4C) 7.5 7.4
Table 1. Maastricht criteria for DCD lungs.
Category Description Type
I Dead on arrival (DoA) Uncontrolled
II Unsuccessful resuscitation Uncontrolled
III Awaiting cardiac arrest,
treatment withdrawn
Controlled
IV Cardiorespiratory arrest during/after
diagnosis of brain death
Controlled
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conventional organ storage solution, we aim to better com-
prehend the modus operandi of Somah and its potential
beneﬁts. In order to construct the optimal manner of pul-
monary graft preservation, it is mandatory to have a broad
understanding of tissue and solution interaction over time.
We evaluated the metabolomics and redox state of por-
cine Maastricht category I-like DCD lungs, statically stored
in cold (4C) LPD or Somah solution. Understanding the
inﬂuence of diﬀerent preservation solutions may provide an
opportunity to expand the donor pool of lungs by safe-
guarding or modulating the metabolic state of DCD lungs
prior to transplant.
Methods
Storage solutions
Somah was purchased from Somahlution (Jupiter, FL,
USA) and Perfadex LPD solution was purchased from
XVIVO Perfusion (Gothenborg, Sweden). Solutions
were freshly prepared on the day of the experiment.
Preservation solutions were randomly assigned to one
lung per experiment and blinded to researchers handling
the organs.
Organ procurement
Organs were procured from Yorkshire pigs (50–60 kg) at the
University of Arizona Food Product and Safety
Laboratory, in accordance with United States Department
of Agriculture and University of Arizona regulations. Pigs
were sacriﬁced by electrocution and rapidly exsanguinated
without anesthetics before organ harvest. Due to the trau-
matic nature of the injury, these circumstances mimic the
Maastricht I-like criteria. The lungs were randomly assigned
to either LPD or Somah and individually rinsed with 1L of
preservation solution by anterograde ﬂushing through the
pulmonary trunk, while ensuring exclusive ﬂow through
either the right or left pulmonary artery by temporarily seal-
ing the contralateral vessel using Kelly forceps (Fig. 1).
Fig. 1. Schematic overview of experimental set-up. Pigs were shocked and rapidly exsanguinated without anesthetics before organ harvest. The
lungs were randomly assigned to either LPD or Somah and individually rinsed with 1 L of preservation solution by anterograde flushing through
the pulmonary trunk. Subsequently the lungs were surgically separated and submerged in their respective preservation solution. Medium samples
and lung biopsies were taken from the before introducing the preservation solution to the lungs (t¼ 0) and at t¼ 2 h, t¼ 6 h, and at t¼ 12 h.
Tissue biopsies and solution samples were immediately snap frozen in liquid nitrogen and stored at 80C.
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Subsequently the lungs were surgically separated and
submerged in their respective cold preservation solution.
As a result of splitting the lung pairs into two separate
lungs, biological variability was minimized. This way, each
animal used in the study is represented in both the LPD and
the Somah group. Lungs that were not ﬂushed, split, and
submerged within 60min after circulatory death of the pig
were excluded from our study.
Experimental procedure
Samples (5mL) were obtained from the preservation solu-
tion before submerging the lungs (t¼ 0 h) and then at t¼ 2 h,
t¼ 6 h, and t¼ 12 h post submersion (Fig. 1). Similarly,
tissue biopsies (1 g each) were obtained from the apex of
the inferior lobe of the lungs at the same time points. Tissue
biopsies and solution samples were immediately snap frozen
in liquid nitrogen and stored at 80C until further process-
ing for analyses.
Metabolic analysis
Metabolomic and statistical analyses were conducted at
Metabolon, Inc. (Durham, NC, USA) as described previ-
ously.21 Brieﬂy, tissue samples were homogenized
(Covaris), then all samples were subjected to methanol
extraction then split into aliquots for analysis by ultrahigh
performance liquid chromatography/mass spectrometry
(UHPLC/MS) in the positive (two methods, one optimized
for hydrophilic, the other hydrophobic compounds), nega-
tive or polar ion mode. Metabolites were identiﬁed by auto-
mated comparison of ion features to a reference library of
chemical standard followed by visual inspection for quality
control.22 For QA/QC, a pooled client matrix (or for
plasma, an internal matrix) as well as several internal stand-
ards were assessed to determine instrument variability, with
RSD¼ 3% (lung or medium) for internal standards and
RSDs¼ 7% (lung) and 9% (medium) for endogenous bio-
chemicals. For statistical analyses and data display, any
missing values were assumed to be below the limits of detec-
tion; these values were imputed with the compound min-
imum (minimum value imputation). To determine
statistical signiﬁcance, a repeated-measures two-way
ANOVA was performed in ArrayStudio (Omicsoft) or
‘‘R’’ on log-transformed data to compare data between
experimental groups; P< 0.05 was considered signiﬁcant.
An estimate of the false discovery rate (Q-value) was calcu-
lated to take into account the multiple comparisons that
normally occur in metabolomic-based studies, with
Q< 0.05 used as an indication of high conﬁdence in a result.
Redox potential analysis
Redox analysis was performed using RedoxSYS Diagnostics
System (Aytu BioScience, Englewood, CO). The balance of
all oxidants and reductants in each sample is measured as
static oxidation reduction potential (sORP), which is an
indicator for the oxidative stress a sample is subjected to.
The driving current over the sample is measured in millivolts
(mV). Lower values indicate less oxidative stress. Capacity
oxidation reduction potential (cORP), also known as total
antioxidant capacity (TAC), is measured in microcoulombs
(mC) and expresses the antioxidant reserve in samples.
Higher values are indicative of a higher ROS scavenging
capacity.23
Results
Glutathione metabolism
Somah demonstrated higher basal (t¼ 0) concentration of
reduced glutathione (GSH) in the medium than LPD
(P< 0.05; Fig. 2a). GSH was rapidly depleted from the
Somah medium, leading to comparable concentrations of
GSH in both mediums after 2 h. Oxidized glutathione
(GSSG) remained stably elevated in Somah medium over
LPD during the entire experiment (P< 0.05; Fig. 2b).
Fig. 2. (a) Reduced glutathione (GSH) in Somah and LPD medium
over time. (b) Oxidized glutathione (GSH) in Somah and LPD medium
over time.
n¼ 3 for each group, plotted values are mean SEM, *P< 0.05.
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Carnitine and carnosine metabolism
Both carnitine and carnosine levels in Somah medium
were signiﬁcantly higher during all time points (P< 0.05;
Fig. 3a, b). In the tissue biopsies, signiﬁcantly increased
levels of carnitine were found in the Somah group at t¼ 2
and were persistent during the entire experiment (P< 0.05;
Fig. 3c). In addition to this ﬁnding, acetylcarnitine, a deriva-
tive from carnitine, and n-acetylcarnosine, an antioxidant
intermediate in the histidine pathway, followed a similar
trend in the biopsies. Though basal levels were not signiﬁ-
cantly diﬀerent between groups, biopsies of lungs in Somah
group contained statistically signiﬁcant higher
acetylcarnitine and n-acetylcarnosine values (P< 0.05;
Fig. 3d, e). The Somah group exhibited higher values of
n-acetylcarnosine in the medium throughout (P< 0.05;
Fig. 3f).
Adenosine metabolism
Adenosine-enriched Somah solution demonstrated signiﬁ-
cantly higher adenosine concentration in the medium
throughout the experiment, with adenosine gradually
Fig. 3. (a) Carnitine in Somah and LPD medium over time. (b) Carnosine in Somah and LPD medium over time. (c) Carnitine in Somah and LPD
lung biopsies over time. (d) Acetylcarnitine in Somah and LPD lung biopsies over time. (e) n-acetylcarnosine in Somah and LPD lung biopsies over
time. (f) n-acetylcarnosine in Somah and LPD medium over time.
n¼ 3 for each group, plotted values are mean SEM, *P< 0.05.
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depleting during the entire 12 h (P< 0.05; Fig. 4a). Tissue
samples showed no diﬀerences in adenosine between groups
(Fig. 4b).
Along with adenosine catabolization, inosine in Somah
medium increased gradually, a trend not found in LPD
(P< 0.05; Fig. 4c). Inosine levels in Somah-preserved lung
tissue were elevated at the beginning of the experiment and
increased over time; the diﬀerence between groups did not
reach statistical signiﬁcance until t¼ 12 (P< 0.05; Fig. 4d).
Carbohydrate metabolism
Somah contains higher basal levels of glucose, malate,
and fumerate, while fructose is higher in LPD (P< 0.05;
Fig. 5a–d). Citric acid (TCA) cycle intermediates showed
larger increments in Somah than in LPD across all time
points (P< 0.05; Table 3). In tissue samples, signiﬁcantly
higher mannitol/sorbitol was found when preserved in
LPD after t¼ 2 (P< 0.05; Fig. 5e). Malate in the tissue
showed a trend of greater increase in Somah than LPD,
but did not reach statistical signiﬁcance (Fig. 5f).
Redox state
Samples of LPD medium demonstrated elevated levels of
sORP compared to Somah samples during the entire pres-
ervation (P< 0.05; Fig. 6a). Levels of cORP in Somah
medium were signiﬁcantly higher at each time point than
LPD (P< 0.05; Fig. 6b).
Discussion
Limited ex vivo storage time has been one of the main
restricting factors in the pulmonary transplant success
rate. Trials exploring the potential of EVLP as a preser-
vation standard provide exciting prospects, but are
increasingly aiming to rejuvenate marginal grafts rather
than increasing preservation time. Moreover, EVLP has
limitations that impede widespread usage of continuous
perfused preservation. The need for improved cold static
storage of donor lungs therefore remains unabated.
Current static lung preservation protocols often lead to
the transplantation of a marginal graft and may lead to
the organ being rejected. Extending ex vivo storage time
with the right conditions would ensure better quality of
organs transplanted. In addition to this enormous beneﬁt,
the organs’ transplantable geographic radius would
increase, providing the optimal HLA-match, and ideally
facilitating a global organ donor program. However, little
is known about the metabolomics of the lung allograft at
hypothermia with the current golden standard lung trans-
plant preservation solution, LPD. We evaluated the meta-
bolomics pathways of the current practice organ
preservation medium and compared the eﬀects and
Fig. 4. (a) Adenosine in Somah and LPD medium over time. (b) Adenosine in Somah and LPD lung biopsies over time. (c) Inosine in Somah and
LPD medium over time. (d) Inosine in Somah and LPD lung biopsies over time.
n¼ 3 for each group, plotted values are mean SEM, *P< 0.05.
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implications of a novel solution on cellular and mitochon-
drial metabolism during cold static storage of porcine
DCD lungs. Our study shows that LPD is unable to scav-
enge ROS eﬀectively at hypothermia. ROS is a major
cause of tissue apoptosis and necrosis in IR injury.
Both the lack of antioxidants and the redox status seen
in the medium raise questions about the current use of
LPD. Somah’s ROS scavenging ability could be an
enhancing alternative. Another important cytoprotective
agent that is missing in LPD is adenosine, which is sup-
plemented in Somah’s formula. The reduction of adeno-
sine along with the elevation in inosine, as observed in the
Somah medium, are strong indicators of active adenosine
catabolism during organ storage. LPD does not provide
cellular protection or inﬂammatory modulation in a simi-
lar manner. Better characterization of the metabolomics
in donor lung organ preservation solutions leads us to
understanding the foundations of limited longevity when
lungs are stored in cold LPD. It also gives an insight on
how Somah may better protect or possibly even recondi-
tion DCD marginal lungs. This could theoretically pre-
vent IR injury following lung transplantation and
thus improve primary graft dysfunction and transplant
outcomes.
Fig. 5. (a) Glucose in Somah and LPD medium over time. (b) Fructose in Somah and LPD medium over time. (c) Malate in Somah and LPD
medium over time. (d) Fumarate in Somah and LPD medium over time. (e) Malate in Somah and LPD lung biopsies over time. (f) Mannitol/sorbitol
in Somah and LPD lung biopsies over time.
n¼ 3 for each group, plotted values are mean SEM, *P< 0.05.
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Glutathione metabolism
Depletion of glutathione pathway intermediates in Somah
medium after 2 h suggests tissue utilization of these sub-
strates. This reduction might be indicative of ROS scaven-
ging and redox potential stabilization. GSH and GSSG can
be used as a marker for oxidative stress.24–26 The penetra-
tion of GSH appears to be suboptimal due to the static
environment. It could be suggested that the tissue penetra-
tion would be better if the organ were continually perfused.
Combining the beneﬁts of continuous organ perfusion by
EVLP and an optimal preservation solution that features
higher glutathione metabolism has enormous potential in
the search for increasing ex vivo graft storage time.
Carnitine and carnosine metabolism
Carnitine has an important role as a transporter of fatty
acids over the mitochondrial membrane. The increase in
carnitine in Somah lungs implies b-oxidation progression
into the TCA-cycle and ATP production. More importantly,
a deﬁcit in carnitine during ischemic periods can cause a
defect in metabolic processing and ATP production upon
reperfusion.27
Furthermore, carnitine plays a role in gluconeogenesis
through fatty acid oxidation as well as being a stabilizing
agent in cell membranes,28,29 providing protection against
cytotoxic free fatty acids.
In addition to these ﬁndings, carnosine intermediates
found in Somah-preserved lungs highlight a strong ROS
scavenging role. This further supports the suggested
antioxidant capacity of Somah. The accumulation of
Table 3. TCA cycle components in preservation solutions over time; n¼ 3 for each sample.
Media Perfadex 0 h Perfadex 2 h Perfadex 6 h Perfadex 12 h Somah 2 h Somah 6 h Somah 12 h Perfadex 2 h Perfadex 6 h Perfadex 12 h 
Biochemical Somah 0 h Somah 2 h Somah 6 h Somah 12 h Somah 0 h Somah 0 h  Somah 0 h Perfadex 0 h Perfadex 0 h Perfadex 0 h 
Citrate 0.6 1.8 1.62 1.28 3.36 4.78 6.58 10.05 12.86 14.08 
Alpha-ketoglutarate 1.35 0.99 0.82 0.6 13.77 22.73 32.41 10.18 13.82 14.4 
Succinate 0.43 0.35 0.33 0.3 5.58 8.47 10.17 4.54 6.39 7.13 
Fumarate 0.01 0.02 0.02 0.02 2.88 3.65 3.81 7.21 9.8 9.99 
Malate 0 0.01 0.01 0.01 0.91 0.97 0.95 25.25 23 21.75 
0.55 Green: indicates significant difference (P  0.05) between the groups shown, metabolite ratio of < 1.00 
0.76 Light green: narrowly missed statistical cutoff for significance 0.05 < P < 0.10, metabolite ratio of < 1.00 
1.71 Red: indicates significant difference (P  0.05) between the groups shown; metabolite ratio of  1.00 
1.32 Light red: narrowly missed statistical cutoff for significance 0.05 < P < 0.10, metabolite ratio of  1.00 
1.20 Non-colored text and cell: mean values are not significantly different for that comparison
Fig. 6. (a) Static oxidation reduction (sORP) in millivolts (mV) of
Somah and LPD medium over time. (b) Capacity oxidation reduction
potential (cORP) in microcoulombs (mC) of Somah and LPD medium
over time.
n¼ 3 for each group, plotted values are mean SEM, *P< 0.05.
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acetylcarnosine in lung tissue can play a vital, beneﬁcial role
against ROS upon reperfusion of the lungs. Carnitine and
carnosine levels are signiﬁcantly higher after t¼ 2 in Somah-
preserved lung tissue and in Somah solution itself, implying
the beneﬁts of increased carnitine and carnosine uptake are
seen in the Somah group and not the LPD group.
Adenosine metabolism
Adenosine in preservation solutions has notable inﬂuences
on multiple levels. We have previously shown that adenosine
has a cytoprotective role;30,31 in lungs it is of great import-
ance to protect cellular function during ischemic periods.
Once the organ is transplanted, immediate and adequate
functioning (i.e. gas exchange) is of vital importance.
Moreover, adenosine possesses anti-inﬂammatory prop-
erties.32,33 During ischemia, adenosine can play a pivotal
role in preventing reperfusion injury.34,35 The absence of
adenosine in LPD raises concerns about the protective
measures on the inﬂammatory response as well as IR injury.
Carbohydrate metabolism
Glucose levels, although being supplemented in both solu-
tions, are higher in the basal formulation of Somah.
Signiﬁcant evidence of diﬀerent carbohydrate metabolism
is found in the basal variation in the medium, as Somah
contains higher malate and fumerate levels and LPD dem-
onstrates increased fructose levels. The eﬀects of this con-
trast may be shown in the tissue biopsies. Lungs preserved in
Somah demonstrate increased TCA cycle utilization, based
on the increase in malate and succinate, whereas LPD lung
tissue showed a muted response, although no statistical sig-
niﬁcance was found. This lack of signiﬁcance might be due
to the hypothermic storage conditions, eﬀectively decelerat-
ing all cellular processes including TCA cycle reactions.
Fructose metabolism in LPD lungs is demonstrated by the
increments of sorbitol over time.
These ﬁnding suggest a better bioenergetic proﬁle for
organs in Somah. This is supported by the accumulation
of glycolytic metabolites such as pyruvate and lactate.
Although this response is seen in both groups, the increase
is greater in Somah medium. Altogether these results indi-
cate the favorable impact of Somah on glycolytic circum-
stances, such as ischemic ex vivo storage.
Redox potential
The increased degree of sORP found in LPD samples are
indicative of elevated oxidative stress, and the lower sORP
levels in Somah highlight its ROS scavenging potential.
Additionally, the cORP results indicate greater antioxidant
capacity in Somah throughout.23 The measurement of sORP
and cORP may provide some beneﬁts over the more stand-
ard methods of ROS assessment. The application of trad-
itional ROS assays has been up for debate as they are
known to have various limitation.36–38 By measuring the
complete static and capacity ORP we aim to overcome the
diﬃculties in ROS measurement, while demonstrating redox
state, of which ROS is an integral part. Combining gluta-
thione assays with redox potential provides a powerful
evaluation of oxidative stress in the tissue.26
A limitation of our study is the absence of reperfusion
after cold static storage. The investigators acknowledge the
pivotal role of oxygen as a mediator of IR injury. As men-
tioned before, mitochondrial rupture upon reperfusion of
the organ with oxygenated blood is a key mediator of
tissue apoptosis. However, given the lack of understanding
of what bioenergetic requirements are met during cold static
storage as well as the protective means of current preserva-
tion solutions, a deeper understanding of the metabolic
pathways was our focus. The present study aims to investi-
gate diﬀerences in metabolic pathways, and experimental
methodology has been developed accordingly. As a result
of the set-up, however, it remains unclear if the eﬀects are
seen locally rather than throughout the entire pulmonary
milieu. We also acknowledge that functional lung param-
eters were unable to be measured at hypothermia in this
experimental setting and that further studies would be
required following reperfusion of DCD lungs.
Lastly, biological variability between the donor pigs
could be regarded as a limitation of our study. Our experi-
mental set-up counteracted this issue by splitting the lungs
before ﬂushing with preservation solution, creating matched
pairs. Thus, each animal was represented in both groups,
with one half of the lung serving as its own control, and
the variation between animals was abated.
Conclusion
There has been little progress over the decade in lung trans-
plantation preservation solutions. Altered cellular metabol-
ism by hypothermia does decelerate energy depletion and
tissue damage, but does not provide circumstances that
exceed the 6 hour ex vivo time limit before critical damage
occurs.39,40 In pursuit of extending this time limit for car-
diothoracic organs it is essential to minimize IR injury. The
formulation of Somah solution could be a logical step
towards maintenance of suﬃcient ATP levels, mitochondrial
integrity and protection against IR injury. Although the
tissue damage occurs upon reperfusion after transplant,
the environment in which the graft is preserved plays a
large role. Insuﬃcient bioenergetic capacity or reserve and
the loss in ATP associated with that is a major trigger for IR
injury. Given the basal formulation of LPD, insuﬃcient
glycolytic capability and heightened fructose metabolism
was expected. Consistent with this we observed an increase
in fructose metabolites. The opposite was seen in Somah
lungs, where the accumulation of TCA cycle components
is representative of a favorable energetic proﬁle upon trans-
plant and glucose enrichment entails more glycolytic cap-
acity, ﬁndings that were expected with Somah’s basal
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formulation. Furthermore, DCD lungs remain underutilized
as transplantable organs after cold static storage. The warm
ischemic times often seen in DCD organ harvest as well as a
cytokine storm and inﬂammation upon cardiac arrest, fur-
ther elucidate the need of preservation approaches that safe-
guard bioenergetic state and possess anti-inﬂammatory
capabilities. Our study illustrates the potential to enhance
metabolic and redox conditions in a way not seen in current
practice with traditional LPD. Lung preservation solutions
have hardly evolved over the past decades and this is under-
lined by insigniﬁcant extension of static ex vivo graft pres-
ervation time. Thus, in conclusion, to increase the lung
donor pool, it is essential to ﬁnd novel approaches that
improve the metabolic state of the organ. Somah does so
in a way that could introduce DCD lungs as an acceptable
alternative resource pool for lung transplant with the poten-
tial of reducing primary graft dysfunction and its sequelae.
Despite the highly encouraging results demonstrated in the
current study, the eﬀects of organ reperfusion after preser-
vation remain unknown, as well as functional lung para-
meters. Studies investigating these factors and outcomes
are needed in order to validate the suggested observations.
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